Extremely aggressive course in a poorly differentiated thyroid carcinoma presenting a double mutation of the TERT promoter.
Molecular marker
Poorly differentiated thyroid carcinoma
TERT promoter mutation
Journal
The American journal of the medical sciences
ISSN: 1538-2990
Titre abrégé: Am J Med Sci
Pays: United States
ID NLM: 0370506
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
04
09
2022
revised:
24
12
2022
accepted:
22
03
2023
medline:
15
5
2023
pubmed:
28
3
2023
entrez:
27
3
2023
Statut:
ppublish
Résumé
BRAF and TERT oncogenes hotspot mutations are associated with a more aggressive outcome in thyroid carcinomas (TC). TERT promoter (pTERT) mutations (C228T and C250T) are related to cancer growth and reduced overall- and disease-free survivals in TC. We report a patient followed up for 8 years with a poorly differentiated thyroid carcinoma (PDTC) presenting an extremely aggressive course, who developed a large volume of metastases in a short period. Molecular analysis of the primary tumor revealed two pTERT mutations (C228T and C250T), and no BRAF V600E mutation. pTERT mutations C228T and C250T have been described as mutually exclusive, indicating that one mutation is enough for telomerase activation and exerts its action in thyroid tumorigenesis. This report describes both pTERT hotspot mutations in the same PDTC patient presenting a very aggressive course, even for PDTC, suggesting a relationship between the two events. However, more studies are needed to prove this causality.
Identifiants
pubmed: 36972734
pii: S0002-9629(23)01119-9
doi: 10.1016/j.amjms.2023.03.019
pii:
doi:
Substances chimiques
prolinedithiocarbamate
135467-92-4
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Telomerase
EC 2.7.7.49
TERT protein, human
EC 2.7.7.49
Types de publication
Case Reports
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
532-537Informations de copyright
Copyright © 2023 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have nothing to declare.